Recent comprehensive reviews of the many GLP-1 agonists that have come to the market in the last 20 years have been published elsewhere [8,37]
doi:10.1093/humrep/dey256 3
But once a few compounds in a category prove clinically useful, it becomes very easy for the rest of the category to borrow that credibility, even when the evidence lags significantly behind
By contrast, glucagon-like peptide-1 agonist (GLP-1A) has shown a strong glucose-dependent hypoglycemic effect with few cardiovascular-related side effects, resulting in a significant market share [3,4,5]
In my experience, the greatest wealth creation happens at these inflection points, when a new technology or behaviour shift is still dismissed by the mainstream but the early signals are unmistakable